Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

Russian bobsledder Sergeeva tests positive for meldonium

Published 03/17/2016, 10:55 AM
Updated 03/17/2016, 11:00 AM
© Reuters. Russia's two-women bobsleigh pilot Sergeeva speeds down the track during unoffical progressive training at the Sanki sliding center in Rosa Khutor near Sochi

By Dmitriy Rogovitskiy

MOSCOW (Reuters) - Russian bobsledder Nadezhda Sergeeva, who competed at the 2014 Sochi Winter Olympics, has tested positive for the banned substance meldonium.

Sergeeva, who finished 16th in the two-person bobsleigh in 2014 with her partner, Nadezhda Paleeva, joins at least 100 other athletes who have recorded positive tests for the drug. The most prominent was the tennis star Maria Sharapova, a five-time grand slam champion.

"I am just shocked about this news, because I am certain that I took this medication only at the end of last year, strictly under the instructions of the doctors from the Federal Medical-Biological Agency as well as cardiologists," the 28-year-old told the R-Sport news agency.

"Of course, both the doctors who prescribed me this substance and I myself were one hundred percent certain that the meldonium would only stay in my system for two or three days and then by 1 January I would be completely clean."

Meldonium was added to the World Anti-Doping Agency's list of banned substances on Jan. 1, 2016. Since then, 100 athletes have been found to have used meldonium, Ben Nichols, WADA's head of communications, said on Tuesday.

At least 11 of them are Russian athletes, including Sharapova, figure skater Ekaterina Bobrova and world champion speed-skater Pavel Kulizhnikov.

Use of meldonium was widespread before its banning. One study showed 490 athletes who competed in last year's European Games in Baku had taken it.

© Reuters. Russia's two-women bobsleigh pilot Sergeeva speeds down the track during unoffical progressive training at the Sanki sliding center in Rosa Khutor near Sochi

Grindeks, the Latvian company that is the main supplier of the drug, says it could protect athletes from cell damage but was unlikely to improve their performance.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.